Patents by Inventor Helen HULS

Helen HULS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20240156929
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: September 12, 2023
    Publication date: May 16, 2024
    Inventors: Laurence J.N. COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • Human application of engineered chimeric antigen receptor (CAR) T-cells
    Patent number: 11786582
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: October 17, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J N Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
  • GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS
    Publication number: 20220072041
    Abstract: Chimeric antigen receptor (CAR) polypeptides (and immune effector cells expressing the CARs) are provided comprising modified hinge domain sequences. Also provided are engineered antigen presenting cells (APCs) that express transgenes encoding target antigen and human leukocyte antigen (HLA). In further aspect, immune effector cells are provided that have been selected for elevated mitochondrial spare respiratory capacity.
    Type: Application
    Filed: July 9, 2021
    Publication date: March 10, 2022
    Inventors: Laurence J.N. COOPER, Harjeet SINGH, Helen HULS, Simon OLIVARES, Bipulendu JENA, Krina PATEL
  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20220062396
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: April 6, 2021
    Publication date: March 3, 2022
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20200085929
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: August 19, 2019
    Publication date: March 19, 2020
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS
    Publication number: 20170333480
    Abstract: Chimeric antigen receptor (CAR) polypeptides (and immune effector cells expressing the CARs) are provided comprising modified hinge domain sequences. Also provided are engineered antigen presenting cells (APCs) that express transgenes encoding target antigen and human leukocyte antigen (HLA). In further aspect, immune effector cells are provided that have been selected for elevated mitochondrial spare respiratory capacity.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 23, 2017
    Inventors: Laurence J.N. COOPER, Harjeet SINGH, Helen HULS, Simon OLIVARES, Bipulendu JENA, Krina PATEL
  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20170224798
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 10, 2017
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY
  • Human application of engineered chimeric antigen receptor (CAR) T-cells
    Patent number: 9629877
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 25, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence JN Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
  • HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
    Publication number: 20160158285
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Application
    Filed: May 14, 2014
    Publication date: June 9, 2016
    Inventors: Laurence JN COOPER, Hiroki TORIKAI, Ling ZHANG, Helen HULS, Feng WANG-JOHANNING, Lenka HURTON, Simon OLIVARES, Janani KRISHNAMURTHY